tiprankstipranks
Advertisement
Advertisement

DE:TKD Stock Latest News

Trump Trade: President warns communities against rejecting data centers
The FlyTrump Trade: President warns communities against rejecting data centers
7d ago
AZN
LLY
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
PremiumThe Fly
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
7d ago
TAK
PTGX
Bayer, Takeda expected to announce new pricing deals with White House, FT says
PremiumThe Fly
Bayer, Takeda expected to announce new pricing deals with White House, FT says
8d ago
AZN
LLY
Protagonist Therapeutics price target raised to $170 from $167 at H.C. Wainwright
PremiumThe Fly
Protagonist Therapeutics price target raised to $170 from $167 at H.C. Wainwright
8d ago
TAK
PTGX
Protagonist announces Takeda received U.S. FDA approval for MIMRYLO
PremiumThe Fly
Protagonist announces Takeda received U.S. FDA approval for MIMRYLO
9d ago
TAK
PTGX
Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO
PremiumCompany AnnouncementsTakeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO
11d ago
Takeda receives FDA approval of NDA for Mimrylo
Premium
The Fly
Takeda receives FDA approval of NDA for Mimrylo
11d ago
TAK
Novavax’s partners approved for Nuvaxovid formulation for vaccination season
Premium
The Fly
Novavax’s partners approved for Nuvaxovid formulation for vaccination season
11d ago
SNY
TAK
Takeda announces Japan MHLW approval for Orzeyful
PremiumThe Fly
Takeda announces Japan MHLW approval for Orzeyful
15d ago
TAK
Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers
PremiumRatings
Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers
26d ago
TAK
Takeda award from Veterans Affairs posted to SAM.gov site
PremiumThe Fly
Takeda award from Veterans Affairs posted to SAM.gov site
29d ago
TAK
Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1
PremiumCompany Announcements
Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1
1M ago
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1
PremiumThe FlyFDA approves Takeda’s Orzeyful to treat narcolepsy type 1
1M ago
TAK
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1 in adults
Premium
The Fly
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1 in adults
1M ago
TAK
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
Premium
The Fly
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
1M ago
TAK
KROS
Mamegano Reiterates Buy on Takeda as Q1 Beat and Pipeline Progress Support Unchanged Price Objective
PremiumRatings
Mamegano Reiterates Buy on Takeda as Q1 Beat and Pipeline Progress Support Unchanged Price Objective
1M ago
TAK
Takeda Delivers Strong Q1 Revenue Growth But Flags Core EPS Decline
PremiumCompany Announcements
Takeda Delivers Strong Q1 Revenue Growth But Flags Core EPS Decline
1M ago
Takeda dengue vaccine receives marketing authorization from India DCGI
PremiumThe Fly
Takeda dengue vaccine receives marketing authorization from India DCGI
2M ago
TAK
Takeda, the Indoensian Government announce collaboration
PremiumThe Fly
Takeda, the Indoensian Government announce collaboration
2M ago
TAK
Takeda Finalizes Share Issuance for Global Employee Incentive Plan
PremiumCompany AnnouncementsTakeda Finalizes Share Issuance for Global Employee Incentive Plan
2M ago
Takeda CEO Christophe Weber retires, Julie Kim succeeds
Premium
The Fly
Takeda CEO Christophe Weber retires, Julie Kim succeeds
3M ago
TAK
Takeda Names Julie Kim CEO and Strengthens Board for Next Growth Phase
Premium
Company Announcements
Takeda Names Julie Kim CEO and Strengthens Board for Next Growth Phase
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >